Latest SEC filings for Moderna, Inc. (MRNA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-31.
Moderna, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
Moderna, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Hoge Stephen, listed as President at Moderna, Inc., reported an open-market sale of 53,336 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Hoge Stephen filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
McDonnell Michael R. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Moderna, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Banque Soria Ester (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
SAGAN PAUL filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Hoge Stephen, listed as President at Moderna, Inc., reported an open-market sale of 53,336 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Hoge Stephen filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
Klinger Shannon Thyme, listed as Chief Legal Officer at Moderna, Inc., reported an open-market sale of 3,471 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Executives, directors, and large shareholders must report any purchase or sale of MRNA shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that Moderna, Inc. must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Moderna, Inc.'s financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the MRNA stock analysis page.